



## Principal Investigator in Biomedical Discovery Research (Two Positions)

### Position Summary

The [Lunenfeld-Tanenbaum Research Institute](#) (LTRI) of [Sinai Health](#), a University of Toronto affiliated biomedical research centre, is seeking two (2) emerging leaders in the broad area of **Biomedical Discovery Research**. The appointments will be for Full-Time Principal Investigators (rank equivalent to Assistant Professor).

We seek applicants to develop innovative, outstanding and independent programs, with either a wet lab or combined computational and wet lab focus. Research approaches include, but are not limited to, the application of functional genomics, proteomics, metabolomics, chemical biology, single-cell biology, live cell imaging, structural biology and cell/tissue engineering to investigate biological processes or develop new therapeutic approaches using human models and/or model organisms. We are particularly interested in investigators with a focus on one of the following topics: **(i) Systems, Cellular, Chemical or Molecular Biology focusing on studying and/or treating human diseases (broad biomedical sciences)** such as network and systems biology, regenerative biology, immunology/microbiology, next-generation therapeutics, cellular physiology, and disease mechanisms; and **(ii) One position will be reserved for candidates who focus on stem cell biology and tissue engineering and their applications to trauma, maintenance, and regeneration of mesenchymal tissues**. The successful candidate will be the inaugural holder of the Tanenbaum Chair in Musculoskeletal Regenerative Medicine at Sinai Health and the University of Toronto.

The successful candidates will join the Lunenfeld-Tanenbaum Research Institute, whose [faculty members](#) are internationally renowned for their work in multiple areas of cutting-edge research. The Institute is committed to excellence in health research and the training of young investigators. The Institute provides a research-intensive environment with modern and innovative core facilities that include proteomics, single-cell and spatial genomics platforms, robotics and imaging that drive technology development and are housed in the [Network Biology Collaborative Centre](#). Sinai Health is also the home of [The Centre for Phenogenomics](#), a state-of-the-art facility for mouse models, and is a founding member of the [Nanoscale Biomedical Imaging Facility](#).

The Lunenfeld-Tanenbaum Research Institute research groups engage in productive collaborations with the larger University of Toronto community, as well as national and international networks. The University of Toronto has one of the most concentrated biomedical research communities in the world, and is home to the Toronto Academic Health Science Network ([TAHSN](#)). Toronto is a vibrant, safe and multicultural city with excellent quality of life.

### Education and Experience Requirements

Candidates must hold a PhD, ScD or equivalent doctoral degrees, with postdoctoral experience and an established record of research accomplishment as demonstrated by outstanding publications, presentations at major international conferences, awards and accolades, and strong endorsement by referees. A track record of securing external funding is an asset. The successful candidate will be expected to initiate and lead an innovative, independent, and externally funded, research program of the highest international calibre.

The Lunenfeld-Tanenbaum Research Institute and Sinai Health are strongly committed to diversity within its community and welcome applications from racialized persons/persons of colour, women, Indigenous/Aboriginal People of North America, persons with disabilities, members of sexual minority groups, and others who may contribute to the further diversification of ideas.

### How to Apply

For more details and how to apply, visit <https://apply.interfolio.com/152420> or scan the QR code. Applications should be submitted via Interfolio prior to **October 20, 2024**. The search will remain open until a suitable candidate is identified. The anticipated start date is September 1, 2025, or to be mutually agreed upon. E-mailed applications will not be accepted.

